

Applied Medical Research

The cost of radiotherapy for 5-year local control and overall survival benefit V. Batumalai¹⁻³, K. Wong¹⁻³, J. Shafiq^{2,3}, T. Hanna², G. Gabriel^{2,3}, J. Heberle⁴, I. Koprivic⁴, N. Kaadan¹, O. King¹, T. Tran¹, L. Cassapi¹, D. Forstner¹, G.P. Delaney¹⁻³, M. Barton¹⁻³

¹Department of Radiation Oncology, South Western Sydney Local Health District; ²Collaboration for Cancer Outcomes Research and Evaluation, Ingham Institute for Applied Medical Research; ³South Western Clinical School, University of New South Wales, Australia; ⁴Activity Based Management, New South Wales Health, Australia


Introduction	Results
Identifying the optimal allocation of	• The average cost per fraction for all cancers was AU\$276


resources to improve health is a major challenge to policy makers. The rapid uptake of new treatment strategies over the last decade in an under-resourced global environment highlights the need to develop a better understanding of costs and benefits of radiotherapy (RT).

Aim

To estimate the costs of 5-year local control and overall survival benefits of radiotherapy in Australia.

- THE AVELAGE COST PET HACHOH IOF AN CANCERS WAS AU\$270.
- The estimated cost benefit of RT was AU\$23,585 per 5year local control and AU\$86,480 per 5-year overall survival for all cancers.





Activity based costing was used to allocate cost to all RT activities extracted from the local RT information Figure 1: Cost per local control (a) and cost per overall survival (b).

Implications

• The cost of AU\$86,480 would translate to AU\$17,296

system (July 2016 to June 2017)

Cost per fraction

Cost per activity (fraction) was determined by dividing the average total cost per patient by the average number of activities

Cost per benefit

Cost per LC=(No. of fractions/LC) X cost per fraction Cost per OS=(No. of fractions/OS) X cost per fraction for 1-year overall survival gain. Therefore, the cost of radiotherapy is inexpensive if delivered optimally.

• Policy implications from this study include knowledge about cost to deliver radiotherapy to allow for valuation of the expected benefit at a population level.

Acknowledgement

This study was supported by Cancer Institute NSW.

Contact

<u>Vikneswary.Batumalai@health.nsw.gov.au</u> Ingham Institute